Biohaven (BHVN) News Today

Biohaven Ltd. (NYSE:BHVN) shares have increased today, driven by favorable regulatory news around its rare‐disease candidate troriluzole and upbeat analyst commentary. Offsetting these gains are rising put‐option activity and a flurry of securities‐litigation notices, which may temper investor enthusiasm.

Key drivers include:

• Positive Sentiment: FDA cancels its planned advisory committee meeting for troriluzole, potentially speeding the drug’s review process Biohaven shares jump as FDA cancels advisory meeting for rare disease drug
• Positive Sentiment: William Blair analyst Myles Minter reiterates a Buy rating, citing regulatory progress and the market potential of troriluzole Optimistic Buy Rating for Biohaven Ltd. Driven by Regulatory Progress and Market Potential of Troriluzole
• Positive Sentiment: BTIG Research raises its price target on BHVN stock from $59 to $60 and maintains a Buy rating BTIG Research Issues Positive Forecast for Biohaven (NYSE:BHVN) Stock Price
• Neutral Sentiment: Unusual options activity: investors bought 6,827 put options—a 203% jump over average volume—signaling some hedging or bearish bets.
• Negative Sentiment: Multiple law firms, including Levi & Korsinsky, Rosen, Faruqi & Faruqi, Pomerantz and others, have filed or announced class-action securities lawsuits against Biohaven, with a September 12, 2025 lead-plaintiff deadline Securities Lawsuit Alert: Biohaven Ltd. (BHVN) Investors